UAB gets $12M contract for anthrax vaccine study

The University of Alabama at Birmingham has received a five-year, $12 million contract from the National Institute of Allergy and Infectious Diseases, to study genetic factors that influence how well individuals respond to the anthrax vaccine. "This research will provide valuable information about individual differences in immune response and in adverse reactions to the anthrax vaccine," said Dr. Richard Kaslow, professor of epidemiology in UAB's School of Public Health.
The national anthrax vaccine trial, funded by the Centers for Disease Control and Prevention, is aimed at determining whether the vaccine is equally safe and effective when injected into muscle rather than under the skin. It also examines an altered dosage schedule.
UAB is one of six medical institutions across the country contributing to the trial. full story